-

Investor Notice: Robbins LLP Informs Investors of the Vital Farms, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Vital Farms, Inc. (NASDAQ: VITL) securities between May 8, 2025 and February 26, 2026. Vital Farms purports to be an ethically minded food company that became the leading U.S. brand of pasture-raised eggs and second largest U.S. egg brand by retail dollar sales.

Robbins LLP is Investigating Allegations that Vital Farms, Inc. (VITL) Misled Investors Regarding its Business Prospects

Share

For more information, submit a formemail attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Vital Farms, Inc. (VITL) Misled Investors Regarding its Business Prospects

According to the complaint, during the class period, defendants made false and misleading statements because: (1) defendants emphasized the importance of implementing the enterprise resource planning ("ERP") system to Vital Farms’ operations and that it was “fundamental to the operational improvements we are planning”; (2) stated the implementation of the ERP would require the time and attention of “management and key crew members”; (3) indeed, defendant Wrede stated that Vital Farms pushed back the expected implementation date of the ERP to “ensure flawless switchover”; (4) given the stated importance of and management’s knowledge of the issues surrounding the implementation of the ERP, defendants knew, or were reckless in not knowing, that implementing the ERP would result in delays of shipments and/or production; (5) defendants did not warn investors that implementing the ERP would result in delays in shipments and/or production, instead merely couching it as a hypothetical in their risk disclosures; and (6) as a result of the delay in shipments and/or production, Vital Farms would lose important retail shelf space, which would negatively impact Vital Farms’ business and operations.

Plaintiff alleges that on February 26, 2026, Vital Farms filed an annual report on a Form 10-K for the fiscal year ended December 28, 2025, revealing that Vital Farms’s revenue for fiscal year 2025 was $759,444,000, missing its guidance of $775,000,000. Furthermore, the Company missed the earnings per share (“EPS”) consensus, reporting EPS of $0.35 versus market consensus of $0.39. The 2025 10-K also revealed that the Company experienced "temporary disruptions in order and fulfillment levels following the launch date of the new ERP system.” On this news, Vital Farms stock declined by $2.68 per share, or 10.8%, to close at $22.11 on February 26, 2026.

What Now: You may be eligible to participate in the class action against Vital Farms, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Vital Farms, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:VITL

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom